Abstract
Local interventions improve the prognosis of patients with non-small-cell lung cancer (NSCLC) and can, in many cases, enable long-term survival. This is not just true for early-stage patients but also for selected patients with operable singular intra- or extrathoracic metastases. This article focuses on the use of bimodal treatment in stage IIIA/IIIB disease, exploration of the mediastinum, trimodal therapy in the case of patients with N2 disease identified prior to treatment, curative resection in metastatic disease, and the use of stereotactic radiation therapy in NSCLC.
Copyright 2010 S. Karger AG, Basel.
MeSH terms
-
Adrenal Gland Neoplasms / drug therapy
-
Adrenal Gland Neoplasms / pathology
-
Adrenal Gland Neoplasms / secondary
-
Adrenal Gland Neoplasms / surgery
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / pathology
-
Brain Neoplasms / secondary
-
Brain Neoplasms / surgery
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / secondary*
-
Carcinoma, Non-Small-Cell Lung / surgery*
-
Chemotherapy, Adjuvant
-
Combined Modality Therapy
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Lung Neoplasms / surgery*
-
Lymphatic Metastasis / pathology*
-
Neoadjuvant Therapy
-
Neoplasm Staging
-
Radiosurgery*
-
Survival Rate